Monday Apr 7
Kaleo Announces $150 Million Debt Financing To Support Commercialization Of EVZIO
Under the financing, PDL provided in cash at closing and will receive interest on the principal outstanding.
PDL BioPharma Sees Significant Decrease in Short Interest
Shares of PDL BioPharma saw a significant decrease in short interest during the month of January.
PDL BioPharma Updates on First Quarter 2014 Revenue Guidance of $133M
Pursuant to the Settlement Agreement, and Roche confirmed that Avastin, Herceptin, Lucentis, Xolair and Perjeta are licensed products as defined in the relevant license agreements between the parties, and further agreed that Kadcyla and Gazyva are licensed products.
Momentum Indicators for Health Care Equities -- Research on Arena...
The losses were broad based as all the sectors ended the session in negative. The S&P 500 Health Care Sector Index finished the day at 686.44, down 0.37%, while the same has advanced 1.72% in the previous three trading sessions.
The Motley Fool
5 Reasons to Buy PDL BioPharma Inc
The wisdom of investing in stocks that pay dividends will never go out of style.